Invesco Pharmaceuticals ETF
PJP
92 hedge funds and large institutions have $51.8M invested in Invesco Pharmaceuticals ETF in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 19 increasing their positions, 28 reducing their positions, and 11 closing their positions.
0.54% less ownership
Funds ownership: 22.82% → 22.28% (-0.54%)
4% less funds holding
Funds holding: 96 → 92 (-4)
13% less capital invested
Capital invested by funds: $59.6M → $51.8M (-$7.76M)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
32% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Trilogy Capital
Irvine,
California
|
+$1.33M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.09M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$798K |
| 4 |
Goldman Sachs
New York
|
+$580K |
| 5 |
IDA
Intelligence Driven Advisers
Carlsbad,
California
|
+$431K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$2.22M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.59M |
| 3 |
GS
GWN Securities
Palm Beach Gardens,
Florida
|
-$719K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$707K |
| 5 |
Morgan Stanley
New York
|
-$542K |
PJP Hedge Fund Activity: Q2 2025 in Review
92 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q2 2025, worth a combined $51.8M — down 13% from $59.6M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PJP and 8 opened new positions — a net loss of 3 holders — while 28 trimmed existing stakes and 19 added.
The largest buyer was Trilogy Capital, opening a new position worth an estimated $1.33M. The largest seller was Federation des caisses Desjardins du Quebec, cutting an estimated $2.22M.
- 92 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q2 2025, down from 96 in Q1 2025.
- Funds reported $51.8M of Invesco Pharmaceuticals ETF stock for Q2 2025, down 13% quarter-over-quarter.
- 8 funds opened new Invesco Pharmaceuticals ETF positions in Q2 2025 and 11 closed out, a net change of -3 holders.
- The largest Invesco Pharmaceuticals ETF buyer in Q2 2025 was Trilogy Capital, an estimated $1.33M added.
- The largest Invesco Pharmaceuticals ETF seller in Q2 2025 was Federation des caisses Desjardins du Quebec, an estimated $2.22M sold.
Based on aggregated 13F filings for Q2 2025.